Nearly six months after Eli Lilly and Verge Genomics established a neuroscience partnership, the pharmaceutical giant is $98 million in financing This will support the biotechnology’s drug pipeline, including an amyotrophic lateral sclerosis (ALS) drug for human testing.
San Francisco-based Verge’s research uses artificial intelligence to find targets for its small molecule drugs. The startup has created a proprietary database containing human brain tissue from patients with neurodegenerative diseases. The company argues that this “all-human” approach is more suitable for drug discovery than testing in animal models. The company’s initial focus was on the development of drugs that address the genetic drivers of ALS. Verge’s other drug research covers Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies, progressive supranuclear palsy, and schizophrenia.
Verge discovered a series of drugs through its artificial intelligence technology. The most advanced of these is the ALS drug candidate, which targets a lipid kinase called PIKfyve. By achieving this goal, the goal is to restore or improve the function of lysosomes, which are the part of cells that remove problem proteins that can cause disease. Through new financing, Verge said it will advance its PIKfvye targeted molecule into clinical testing in 2022.
Verge signed a partnership with Lilly this summer that covers additional ALS goalsUnder this three-year agreement, Verge will receive $25 million, and partners will use the startup’s technology to verify these goals. Eli Lilly can choose to advance up to four drug candidates through clinical development and commercialization. If any of these drugs enter the market, Verge may receive up to $694 million in milestone payments.
Verge completed $32 million in Series A financing in 2018. BlackRock-managed funds led the B round of financing. In addition to Eli Lilly, new investors joining the latest round include Merck Global Health Innovation Fund, Section 32 and Vulcan Capital. Earlier investors Threshold Ventures, ALS Investment Fund, Tao Capital Partners and Lifeforce Capital also participated.
The cash before Christmas is filing the inventory of other startups. Below are other financing announced on Thursday.
Tasso spends US$100 million to increase production of blood collection equipment
Tasso, a developer of blood collection medical equipment based in Seattle, Closed 100 million dollars In the B round of financing. The Tasso device allows patients to conveniently collect their own blood samples at home. In the financing announcement, CEO Ben Casavant stated that the Covid-19 pandemic has caused a fundamental shift in healthcare, driving the demand for more home solutions. Applications of Tasso blood collection equipment include decentralized clinical trials and remote patient monitoring.
RA Capital Management led Tasso’s new financing. Other new investors in the latest round include DE Shaw Group, Senvest, InCube and SVB Innovation Fund. Earlier investors Foreste Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai and Merck Global Health Innovation Fund also participated. Tasso said it will use the new funds to expand its manufacturing and operations to meet the growing demand for its blood collection equipment and decentralized health testing services.
Brainomix receives £16 million to expand its artificial intelligence platform beyond stroke
Brainomix’s AI platform validates imaging biomarkers that can be used to make diagnosis and treatment decisions. The application of this technology in stroke imaging has gained a place in healthcare systems in Europe and other parts of the world.Now, the Oxford-based start-up company hopes to extend the technology to other therapeutic indications and has already Raised £16 million (Approximately US$21.2 million) to support this work.
Other targets identified by the company include pulmonary fibrosis and cancer. The new cash is a Series B financing and will also support cooperation plans with pharmaceutical companies. These alliances may include clinical trials using the technology, promoting the adoption of current therapies in new indications, and improving patient outcomes. Boehringer Ingelheim Ventures and Parkwalk Advisors led the new round of financing. Tencent Holdings and Oxford University Innovation Fund also joined them.
Photo: Revolution b, Getty Images
